SIGA Technologies, Inc.
Financials
Valuation Metrics
SIGA Technologies, Inc.'s Market Cap is $225M. At end of 2025 it was $438M. Ranked #3009 of 3,121 in US market (top 96%), #1375 of 1,463 on NASDAQ (top 94%), #251 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $225M | US#3,009/3,121 Sec#251/266 |
| Revenue | $54M | US#2,769/3,121 Sec#148/266 |
| Net Income | $-3M | US—/3,121 Sec—/266 |
| Total Assets | $176M | US#3,014/3,121 Sec#251/266 |
| Net Assets | $165M | US#2,730/3,121 Sec#202/266 |
| Employees | 49 | US#2,721/3,121 Sec#212/266 |
| Value | ||
| P/B | 1.36x | US#712/3,121 Sec#25/266 |
| P/S | 4.20x | US#2,102/3,121 Sec#62/266 |
| FCF Yield | -9.10% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -1.67% | US#2,183/3,121 Sec#68/266 |
| ROA | -1.57% | US#2,353/3,121 Sec#78/266 |
| Op. Margin | -20.76% | US#2,609/3,121 Sec#101/266 |
| Revenue Growth | -70.13% | US#2,760/3,121 Sec#175/266 |
| Earnings Growth | -103.35% | US#1,890/3,121 Sec#55/266 |
| Financial Health | ||
| Debt Ratio | 6.32% | US#56/3,121 Sec#25/266 |
| Total Debt | $439397.00 | US#3,004/3,121 Sec#255/266 |
| FCF | $-20M | US#2,429/3,121 Sec#96/266 |
| Cash | $118M | US#2,116/3,121 Sec#162/266 |
| Current Ratio | 21.72x | US#111/3,121 Sec#21/266 |
| Dividend | ||
| Div. Yield | 19.27% | US#14/3,121 Sec#1/266 |
| Div. Growth | 1.06% | US#1,136/3,121 Sec#20/266 |
| Performance | ||
| 1Y Return | -64.60% | US#3,041/3,121 Sec#254/266 |
| 1M Return | 0.96% | US#713/3,121 Sec#71/266 |
| From 52W High | -66.77% | US#2,997/3,121 Sec#241/266 |
| 1Y MDD | -69.37% | US#2,951/3,121 Sec#237/266 |
| Trading | ||
| Volume | 672,205 shares | US#1,708/3,121 Sec#181/266 |
| Trading Value | $2M | US#2,889/3,121 Sec#245/266 |
| Per Share | ||
| EPS | $-0.04 | US—/3,121 Sec—/266 |
| BPS | $2.30 | US#2,554/3,121 Sec#173/266 |
Company Info
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.